Clinical Trial: A Study of CS060380 Tablets in Patients With MASH and Obesity

U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07466017) titled 'A Study of CS060380 Tablets in Patients With MASH and Obesity' on March 02.

Brief Summary: this study is looking at a new investigational medicine called CS060380, when used together with semaglutide, in adults who have both metabolic dysfunction-associated steatohepatitis (MASH) and obesity. MASH is a condition where too much fat builds up in the liver, leading to inflammation and damage. Obesity is a major risk factor for this condition.

This is a Phase II clinical trial, which means we are testing the medicine to see if it works and is safe. The study will last up to 54 weeks, which is a little over a year. It includes:

* A sc...